University Cancer Center Opens Phase I Trial

The University of Kansas Cancer Center is beginning a Phase I trial to study Nanotax, a reformulated version of Paclitaxel, for ovarian cancer.

Scientists have reformulated the chemotherapy drug into a nanoparticle that can be mixed with water and administered to patients in the abdomen. This approach is believed to increase survival rates with the drug as compared with intravenous delivery, according to the university.

The trial will enroll a small number of patients and is part of a collaboration with CritiTech, which has licensed the drug and submitted an NDA to the FDA.